Atossa Therapeutics (ATOS) Rises 12% in October Amid Strong Phase II Pipeline Outlook
Atossa Therapeutics (ATOS) edges up 12% this month with a promising breast‑cancer pipeline and Phase II trials on track—ideal for value investors eyeing a potential upside below its 200‑day average.
- ATOSSA THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read